UK cell therapy biotech lays off 25% of staff, turns to tool development over therapeutics
Cell therapy biotech bit.bio is slimming its workforce down by 25% as the company pivots to focus on biomedical tools instead of drug development.
Cell therapy biotech bit.bio is slimming its workforce down by 25% as the company pivots to focus on biomedical tools instead of drug development.
